AngioDynamics Q3 EPS Estimate Decreased by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at Zacks Research decreased their Q3 2028 earnings per share (EPS) estimates for shares of AngioDynamics in a research report issued on Tuesday, August 4th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn ($0.01) per share for the quarter, down from their prior forecast of $0.03. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.27) per share. Zacks Research also issued estimates for AngioDynamics’ FY2029 earnings at ($0.15) EPS.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

A number of other research analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Canaccord Genuity Group raised their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Finally, HC Wainwright boosted their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Trading Up 0.1%

Shares of NASDAQ:ANGO opened at $15.19 on Wednesday. The stock’s 50-day moving average price is $12.94 and its two-hundred day moving average price is $11.58. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $15.41. The firm has a market cap of $627.80 million, a price-to-earnings ratio of -17.46 and a beta of 0.33.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. The trade was a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently bought and sold shares of ANGO. Franklin Resources Inc. increased its position in shares of AngioDynamics by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock worth $621,000 after acquiring an additional 1,076 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 1,199 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of AngioDynamics by 5.9% during the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock valued at $457,000 after acquiring an additional 1,992 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in AngioDynamics during the 4th quarter worth $27,000. Finally, Price T Rowe Associates Inc. MD boosted its position in AngioDynamics by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock worth $569,000 after purchasing an additional 2,263 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.